Category: Markets
Published: 2026-08-17T17:24:50.000Z
Lexaria Bioscience Corp. announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its stock will continue to be listed and traded on The Nasdaq Capital Market. The company received confirmation from a Nasdaq Hearings Advisor, leading to the cancellation of a previously scheduled deficiency hearing. This resolution follows an earlier notice from Nasdaq regarding its non-compliance with the minimum bid price rule.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.